Google
Trusted Resources: Community Center
Online support, community stories, financial assistance
Dr Gertz on the Investigation of Birtamimab in Mayo Stage IV AL Amyloidosis
Morie A. Gertz, MD, chair, General Internal Medicine, Mayo Clinic Comprehensive Cancer Center, discusses the rationale for the phase 3 AFFIRM-AL trial (NCT04973137) in patients with amyloid light chain (AL) amyloidosis and elaborates on the challenges that may arise when enrolling patients to this trial.
myBinderRelated Content
-
University of Miami Health System, Sylvester Comprehensive Cancer CenterAmyloidosis is a rare protein depositi...
-
FDA OKs Inotersen (Tegsedi) for Hereditary ATTR With PolyneuropathyThe US Food and Drug Administration (FDA...
-
Chicago – Amyloidosis Support Groups Meeting – LIVE – Saturday, September 9, 2023This Meeting Is for AL Amyloidosis Only ...
-
Amyloid Center, Stanford Health CareThe Amyloidosis center at Stanford Healt...
-
CRISPR Gene Editing Reduces Disease-Causing Protein in Hereditary Transthyretin AmyloidosisThe results of the phase 1 study open-la...
-
Learn About Clinical StudiesWhat Is a Clinical Study? A clini...
-
Phase 1/2 Trial of Venetoclax by Dr. Rajshekhar Chakraborty – ASG Webinar – 8/9https://www.youtube.com/watch?v=vP4wvJq5...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
